Tolebrutinib, a brain-penetrant and bioactive Bruton tyrosine kinase inhibitor that modulates persistent immune activation ...

Results of the Phase III HERCULES trial suggest the first potential treatment option for a form of multiple sclerosis.

Cogent Biosciences, Inc.’s COGT share price has dipped by 7.73%, which has investors questioning if this is right time to buy ...

Annual Meeting Clinical Trials Plenary Session, Sanofi presented data on tolebrutinib in patients with non-relapsing ...

A new study has unveiled when chronic myeloid leukemia, a type of cancer that affects the blood and bone marrow, arises in ...

Cogent Biosciences, Inc. topline results for phase 2/3 studies on bezuclastinib targeting systemic mastocytosis & GIST are ...

New research led by a St. Michael's Hospital clinician-scientist and published in the New England Journal of Medicine ...

Tolebrutinib, an experimental drug, slowed disability progression in advanced MS by 31% in a major trial, offering hope for ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions ...

A new study has unveiled when chronic myeloid leukemia, a type of cancer that affects the blood and bone marrow, arises in ...

William Blair initiated coverage on Ocular Therapeutix (NASDAQ:OCUL) with an Outperform rating, setting a fair value target ...

Caris Life Sciences has collected $168 million in new funding to support the growth of its precision medicine platforms, ...